## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>STATEMENT</b>	OF CHANGES	S IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

# Filed pursuant to Section 16(a) of the Securities Eychange Act of 1034

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     SBLENDORIO GLENN													5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
SBLENDURIU GLEININ													X Director		10% Owner		ner	
(Last)	(F	irst)	(Middle)		Date of Earliest Transaction (Month/Day/Year)								Officer (give title below)			Other (s below)	pecify	
C/O OPHTHOTECH CORPORATION			1	12/12/2018								President and CEO						
ONE PENN PLAZA, 35TH FLOOR																		
ONE FERRI FLAZA, 33111 FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable					
(Street)				4.	. II AIII	enament, t	Jale 0	i Original Fil	eu (	wonin/Da	y/ rear)	Lin		Johnstoup	Filling	(Спеск Арр	licable	
NEW YO	ORK N	v	10119										X Form	filed by One	e Repo	rting Person		
	JKK IV	1	10119	_							Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)															
		Ta	ble I - Non-D	orivoti	vo 6	ocuritio	ς Λο.	auirod D	icn	ocod o	f or Po	noficial	v Owno					
					_			<del>-</del>	ıısp				-		1			
1. Title of Security (Instr. 3)  2. Trans Date (Month/			te	action 2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.			Benefic Owned	ies ially Following	Form (D) or	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)					
								Code V Amount		(A) or Price				Transa	Reported Transaction(s)			
								Couc		Amount	(D)	1 1100	(Instr. 3	and 4)				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	nsaction Derivative Ex		6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)	derivativ Securitie Benefici Owned Followin Reported	e es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		piration ate	Title	Amount or Number of Shares		Transact (Instr. 4)	ion(s)			
Stock Option (Right to Buy)	\$1.45	12/12/2018		A		183,500		(1)	12	2/11/2028	Common Stock	183,500	\$0.00	183,5	000	D		
Restricted Stock Units	(2)	12/12/2018		A		91,800		(3)	12	//11/2028	Common Stock	91,800	\$0.00	91,80	00	D		

#### **Explanation of Responses:**

- 1. Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, each of these stock option awards will vest as follows: (1) no shares underlying the option shall vest unless, for a period of twenty consecutive trading days, the average closing sale price of the Registrant's common stock is equal to or exceeds 125% of the exercise price per share of such option (the "Performance Condition"), (2) subject to satisfaction of the Performance Condition, the option shall vest with respect to 25% of the shares subject to the option on the first anniversary of the grant date and with respect to the remaining shares in approximately equal monthly installments through the fourth anniversary of the grant date, and (3) such stock option shall be subject to "double-trigger" acceleration of vesting upon termination of employment following a change in control of the Registrant.
- 2. Each restricted stock unit represents the contingent right to receive one share of common stock upon vesting of the unit.
- 3. Subject to continued employment with the Registrant and the other terms and conditions under the Registrant's 2013 Stock Incentive Plan, the award of restricted stock units will vest with respect to 25% of the shares subject to the award on each of the first, second, third and fourth anniversaries of the grant date.

### Remarks:

Exhibit Index: 24.1 Power of Attorney

/s/ Todd Anderman, as

Attorney-in-Fact for Glenn P. 12/14/2018

Sblendorio

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

#### POWER OF ATTORNEY

Know all by these presents that the undersigned hereby constitutes and appoints each of David F. Carroll and Todd Anderman, or either of them signing singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

- (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended, or any rule or regulation of the SEC:
- (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Ophthotech Corporation (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder;
- (3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the SEC and any stock exchange or similar authority; and
- (4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934, as amended.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of December, 2018.

/s/ Glenn P. Sblendorio	
Signature	
Glenn P. Sblendorio	
-	_